Suppressing the antibody response with Siglec ligands
L Nitschke - New England Journal of Medicine, 2013 - Mass Medical Soc
New England Journal of Medicine, 2013•Mass Medical Soc
Suppressing the Antibody Response with Siglec Ligands | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career with
NEJM Group information and services. NEJM Evidence NEW! A digital journal for innovative
original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career with
NEJM Group information and services. NEJM Evidence NEW! A digital journal for innovative
original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
Production of antibodies to self-antigens is a risk factor for autoimmune disease. A potential strategy to suppress production of specific antibodies by B cells may involve stimulation of a class of “repressor” receptors, the sialic acid–binding immunoglobulin-like lectins.
The New England Journal Of Medicine